COMP <GO>
RGEN vs UNH // GROSS PROFIT MARGIN
Repligen Corporation (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: RGEN 3
— UNH 12
▲ GROSS PROFIT MARGIN LEADER: UNH
LAST: $176.94 (-6.20%) • MKT CAP: $10.69B
gross-margins
88.20%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
gross-margins
88.57%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGEN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RGEN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 88.20% | 88.57% | -0.37 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.30% | 11.47% | -9.17 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 16.4x | +78.55 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 0.88% | 6.48% | -5.60 | UNH | /fcf-yield <GO> |
| Operating Margin | 1.80% | 4.82% | -3.02 | UNH | /operating-margins <GO> |
| Net Profit Margin | 1.60% | 3.14% | -1.54 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 6.46% | -9.76 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.31 | 3.12 | +6.19 | RGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | RGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.74% | +0.26 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 56.0 | -7.39 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.33 | +0.71 | RGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 17.1x | +122.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.69B | $364.66B | -$353.96B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RGEN REV | UNH REV | RGEN GROSS % | UNH GROSS % | RGEN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $447.57B | — | 88.7% | $93.9M | $16.07B |
| FY 2024 | $0 | $400.28B | — | 88.3% | $149.7M | $20.70B |
| FY 2023 | $0 | $371.62B | — | 89.6% | $113.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGEN // BETA 1.04
UNH // BETA 0.33